Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women

[1] Borgström F(2013)The international costs and utilities related to osteoporotic fractures study (ICUROS)—quality of life during the first 4 months after fracture Osteoporosis Int 24 811-823

[2] Lekander I(2014)Clinician’s guide to prevention and treatment of osteoporosis Osteoporosis Int 25 2359-2381

[3] Ivergård M(2013)Five-year relative survival of patients with osteoporotic hip fracture J Clin Endocrinol Metab 99 97-100

[4] Cosman F(2013)Public health impact of osteoporosis J Gerontol A Biol Sci Med Sci 68 1243-1251

[5] De Beur S(2015)Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the united states Mayo Clin Proc 90 53-62

[6] LeBoff M(2011)Severe osteopenia and osteoporosis, sarcopenia, and frailty status in community-dwelling older women: results from the women’s health and aging study (WHAS) II Bone 48 952-957

[7] Lee Y(2000)Characterization of perimenopausal bone loss: a prospective study J Bone Mineral Res 15 1965-1973

[8] Lee Y(2013)Health risks and benefits from calcium and vitamin D supplementation: women’s health initiative clinical trial and cohort study Osteoporosis Int 24 567-580

[9] Ha Y(2014)Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis Calcif Tissue Int 94 153-157

[10] Koo K(2013)A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data Calcif Tissue Int 92 59-67

[1] Borgström F(2013)The international costs and utilities related to osteoporotic fractures study (ICUROS)—quality of life during the first 4 months after fracture Osteoporosis Int 24 811-823

[2] Lekander I(2014)Clinician’s guide to prevention and treatment of osteoporosis Osteoporosis Int 25 2359-2381

[3] Ivergård M(2013)Five-year relative survival of patients with osteoporotic hip fracture J Clin Endocrinol Metab 99 97-100

[4] Cosman F(2013)Public health impact of osteoporosis J Gerontol A Biol Sci Med Sci 68 1243-1251

[5] De Beur S(2015)Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the united states Mayo Clin Proc 90 53-62

[6] LeBoff M(2011)Severe osteopenia and osteoporosis, sarcopenia, and frailty status in community-dwelling older women: results from the women’s health and aging study (WHAS) II Bone 48 952-957

[7] Lee Y(2000)Characterization of perimenopausal bone loss: a prospective study J Bone Mineral Res 15 1965-1973

[8] Lee Y(2013)Health risks and benefits from calcium and vitamin D supplementation: women’s health initiative clinical trial and cohort study Osteoporosis Int 24 567-580

[9] Ha Y(2014)Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis Calcif Tissue Int 94 153-157

[10] Koo K(2013)A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data Calcif Tissue Int 92 59-67